Mr. Michael McFadden reports

ALPHA COGNITION ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION TO THE FDA FOR ALPHA-1062 FOR MILD-TO-MODERATE ALZHEIMER'S DISEASE

Alpha Cognition Inc. has submitted a new drug application (NDA) to the United States Food and Drug Administration (FDA) for Alpha-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer's disease. This submission marks a significant milestone in the company's continuing commitment to advancing patient care for patients suffering from Alzheimer's disease.

Alpha-1062, a pro-drug of galantamine, is uniquely designed to reduce gastrointestinal adverse effects by remaining inert as it passes through the stomach. Currently approved drugs for Alzheimer's disease are associated with significant adverse events, including nausea, vomiting, diarrhea and insomnia. As a result, it is unpleasant and impractical for many patients to utilize these drugs for extended periods of time, resulting in a significant unmet need for effective and tolerable treatments for Alzheimer's disease.

"We are excited about the potential impact and benefits that Alpha-1062 may have on the lives of patients battling mild-to-moderate Alzheimer's disease. Our team has dedicated years of research and development to bringing this innovative therapeutic option to fruition," stated Michael McFadden, chief executive officer of Alpha Cognition. "The submission of the new drug application is a testament to our unwavering commitment to improving patient outcomes and advancing the treatment of Alzheimer's disease."

The NDA submission is based on results from four studies the company conducted demonstrating bioequivalence for Alpha-1062 to galantamine and galantamine ER. Adverse events documented across all studies for Alpha-1062 were less than 2 per cent and no insomnia was observed. The company expects to receive FDA acceptance of the NDA in Q4 2023.

About Alpha Cognition Inc.

Alpha Cognition is a clinical-stage biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and cognitive impairment with mild traumatic brain injury (mTBI), for which there are currently no approved treatment options.

Alpha-1062 is a patented new chemical entity being developed as a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, with expected minimal gastrointestinal side effects. Alpha-1062's active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Alpha-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer's dementia and as an intranasal formulation for cognitive impairment with mTBI.

We seek Safe Harbor.